Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella‐Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,703

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Macrophage activation and polarization: nomenclature and experimental guidelines

Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857

IDH1 and IDH2 Mutations in Gliomas

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063

The Somatic Genomic Landscape of Glioblastoma

Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016

Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments

Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,890

Fluorescence-Guided Surgery with 5-Aminolevulinic Acid for Resection of Malignant Glioma: A Randomised Controlled Multicentre Phase III Trial

Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423

DNA methylation-based classification of central nervous system tumours

Capper, D., Jones, D., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chávez, L., Reuß, D., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,114

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Andtbacka, R. H. I., Kaufman, H. L., Collichio, F. A., AMATRUDA, T. T., Senzer, N. N., Chesney, J. A., Delman, K. A., S̄pitler, L. E., Puzanov, I. J., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,728

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

Ostrom, Q. T., Cioffi, G., Gittleman, H. R., Patil, N. T., Waite, K. A., Kruchko, C., & Barnholtz‐Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,660

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

Chinot, O. L., Wick, W., Mason, W. P., Henriksson, R., Saran, F. H., Nishikawa, R., Carpentier, A. F., Hoang‐Xuan, K., Kavan, P., Cernea, D. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,653

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644

Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer

Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M. H., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,528

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,516

A restricted cell population propagates glioblastoma growth after chemotherapy

Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

Ceccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,210

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment

Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L. M., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 2,039

The blood–brain barrier and blood–tumour barrier in brain tumours and metastases

Arvanitis, C., Ferraro, G. B., & Jain, R. K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,919

Cancer: Principles and Practice of Oncology.

(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,913

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,847

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,842

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737

An extent of resection threshold for newly diagnosed glioblastomas

Sanai, N., Polley, M. C., McDermott, M. W., Parsa, A. T., & Berger, M. S. (2011) · Journal of neurosurgery · doi:10.3171/2011.2.jns10998 · Cited by 1,685

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Raskob, G. E., van Es, N., Verhamme, P. B., Carrier, M., Nisio, M. D., Garcia, D. A., GROSSO, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586

Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy

Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

Reardon, D. A., Brandes, A. A., Omuro, A. M. P., Mulholland, P. J., Lim, M. K., Wick, A., Baehring, J. M., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,514

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432

Current state of immunotherapy for glioblastoma

Lim, M. K., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,396

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas

Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R. G., Vick, N. A., Black, K. L., Sisti, M. B., Brem, S. S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,390

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

Westphal, M., Hilt, D. C., Bortey, E. B., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J. E., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,374

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

Young, A., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C. S., Hale, D., Dunn, J., Lyman, G. H., Hutchinson, C. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,373

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368

Electrical and synaptic integration of glioma into neural circuits

Venkatesh, H. S., Morishita, W., Geraghty, A. C., Silverbush, D., Gillespie, S. M., Arzt, M., Tam, L. T., Espenel, C., Ponnuswami, A., Ni, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1563-y · Cited by 1,366

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacıoğlu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,282

Glutamatergic synaptic input to glioma cells drives brain tumour progression

Venkataramani, V., Tanev, D. I., Strahle, C., Studier-Fischer, A., Fankhauser, L., Kessler, T., Körber, C., Kardorff, M., Ratliff, M., Xie, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1564-x · Cited by 1,197

State-of-the-art strategies for targeting the DNA damage response in cancer

Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

Perry, J., Laperrière, N., O'Callaghan, C. J., Brandes, A. A., Menten, J. J., Phillips, C., Fay, M. F., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,179

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

Weller, M., van den Bent, M. J., Tonn, J. C., Stupp, R., Preusser, M., Moyal, E. C., Henriksson, R., Rhun, É. L., Balañá, C., Chinot, O. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,152

Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas

Sugahara, T., Korogi, Y., Kochi, M., Ikushima, I., Shigematu, Y., Hirai, T., Okuda, T., Liang, L., Ge, Y., Komohara, Y., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199901)9:1 · Cited by 1,151

Association of the Extent of Resection With Survival in Glioblastoma

Brown, T. J., Brennan, M., Li, M. J., Church, E. W., Brandmeir, N. J., Rakszawski, K. L., Patel, A. S., Rizk, E., Suki, D., Sawaya, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1373 · Cited by 1,138

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Weller, M., Butowski, N. A., Tran, D. D., Recht, L. D., Lim, M. K., Hirte, H. W., Ashby, L. S., Mechtler, L. L., Goldlust, S. A., IWAMOTO, F. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,138

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,136

Impact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis

Hamer, P. C. D. W., Robles, S. G., Zwinderman, A. H., Duffau, H., & Berger, M. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4818 · Cited by 1,100

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052

Lomustine and Bevacizumab in Progressive Glioblastoma

Wick, W., Gorlia, T., Bendszus, M., TAPHOORN, M. J. B., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Dômont, J., Idbaïh, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 1,004

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938

Actively personalized vaccination trial for newly diagnosed glioblastoma

Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938

cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

Brat, D. J., Aldape, K., Colman, H., Holland, E. C., Louis, D. N., Jenkins, R. B., Kleinschmidt-DeMasters, B. K., Perry, A., Reifenberger, G., Stupp, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1913-0 · Cited by 904

Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial

Roa, W., Brasher, P. M. A., Bauman, G. S., Anthes, M., Bruera, E. D., Chan, A., Fisher, B., Fulton, D. S., Gulavita, S. P. P., Hao, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.082 · Cited by 902

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862

Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency

Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857

Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors [RETIRED]

Glantz, M., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 856

Recurrent Glioblastoma Treated with Recombinant Poliovirus

Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N. T., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S. K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 843

Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity

Turner, K. M., Deshpande, V., Beyter, D., Koga, T., Rusert, J. M., Lee, C., Li, B., Arden, K. C., Ren, B., Nathanson, D. A., et al. (2017) · Nature · doi:10.1038/nature21356 · Cited by 835

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835

Adult Glioblastoma

Alexander, B. M., & Cloughesy, T. F. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0119 · Cited by 815

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

Okada, H., Weller, M., Huang, R. Y., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 794

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Taal, W., Oosterkamp, H. M., Walenkamp, A., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D. H., Vos, F. D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 784

Mechanisms of immunotherapy resistance: lessons from glioblastoma

Jackson, C. M., Choi, J. H., & Lim, M. K. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 773

Brain immunology and immunotherapy in brain tumours

Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0224-7 · Cited by 758

Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

Albert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C. J., Pope, W. B., Law, I. G., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 743

Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System

Levin, V. A., Bidaut, L. M., Hou, P., Kumar, A. J., Wefel, J. S., Bekele, B. N., Prabhu, S. S., Loghin, M. E., Gilbert, M. R., & Jackson, E. F. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.061 · Cited by 731

Clonal evolution of glioblastoma under therapy

Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D. I. S., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.-J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3590 · Cited by 720

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

Lang, F. F., Conrad, C. A., Gomez‐Manzano, C., Yung, W. K. A., Sawaya, R. A., Weinberg, J. S., Prabhu, S. S., Rao, G., Fuller, G. N., Aldape, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.8219 · Cited by 718

Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M., Zhelyazkova, B. H., Davidson, C. J., Akhavanfard, S., Cahill, D. P., Aldape, K., Betensky, R. A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.005 · Cited by 717

Molecular targeted therapy of glioblastoma

Rhun, É. L., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M. J., Wen, P. Y., Reifenberger, G., & Weller, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101896 · Cited by 704

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Ellingson, B. M., Bendszus, M., Boxerman, J. L., Barboriak, D. P., Erickson, B. J., Smits, M., Nelson, S. J., Gerstner, E. R., Alexander, B. M., Goldmacher, G., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 700

Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA

Nathanson, D. A., Gini, B., Mottahedeh, J., Visnyei, K., Koga, T., Gomez, G. G., Eskin, A., Hwang, K., Wang, J., Masui, K., et al. (2013) · Science · doi:10.1126/science.1241328 · Cited by 689

Lymphomas and High-Grade Astrocytomas: Comparison of Water Diffusibility and Histologic Characteristics

Guo, A. C., Cummings, T. J., Dash, R. C., & Provenzale, J. M. (2002) · Radiology · doi:10.1148/radiol.2241010637 · Cited by 681

Mechanisms and therapeutic implications of hypermutation in gliomas

Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C. L., Cortés‐Ciriano, I., Birzu, C., Geduldig, J. E., Pelton, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2209-9 · Cited by 680

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors

Chongsathidkiet, P., Jackson, C., Koyama, S., Loebel, F., Cui, X., Farber, S. H., Woroniecka, K. I., Elsamadicy, A. A., Dechant, C. A., Kemeny, H. R., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0135-2 · Cited by 675

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

Woroniecka, K. I., Chongsathidkiet, P., Rhodin, K. E., Kemeny, H. R., Dechant, C. A., Farber, S. H., Elsamadicy, A. A., Cui, X., Koyama, S., Jackson, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1846 · Cited by 670

Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project

Laws, E. R., Parney, I. F., Huang, W., Anderson, F. A., Morris, A. M., Asher, A., Lillehei, K. O., Bernstein, M., Brem, H., Sloan, A. E., et al. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.99.3.0467 · Cited by 669

Clinical Proton MR Spectroscopy in Central Nervous System Disorders

Öz, G., Alger, J. R., Barker, P. B., Bartha, R., Bizzi, A., Boesch, C., Bolan, P. J., Brindle, K. M., Cudalbu, C., Di̇nçer, A., et al. (2014) · Radiology · doi:10.1148/radiol.13130531 · Cited by 663

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Schalper, K. A., Rodriguez-Ruiz, M. E., Díez-Valle, R., López‐Janeiro, Á., Porciuncula, A., Idoate, M. A., Inogés, S., de Andrea, C., de Cerio, A. L.-D., Tejada, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0339-5 · Cited by 653

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid

Miller, A. M., Shah, R. H., Pentsova, E. I., Pourmaleki, M., Briggs, S. R., DiStefano, N. M., Zheng, Y., Skakodub, A., Mehta, S. A., Campos, C., et al. (2019) · Nature · doi:10.1038/s41586-019-0882-3 · Cited by 635

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Stupp, R., Taillibert, S., Kanner, A. A., Read, W. L., Steinberg, D. M., Lhermitte, B., Toms, S. A., Idbaïh, A., Ahluwalia, M. S., Fink, K., et al. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5167/uzh-143757 · Cited by 630

Human glioblastoma arises from subventricular zone cells with low-level driver mutations

Lee, J. H., Lee, J. E., Kahng, J. Y., Kim, S. H., Park, J. S., Yoon, S. J., Um, J.-Y., Kim, W. K., Lee, J.-K., Park, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0389-3 · Cited by 630

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Batchelor, T. T., Mulholland, P. J., Neyns, B., Nabors, B., Campone, M., Wick, A., Mason, W. P., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 623

Oncolytic Viruses in Cancer Treatment

Lawler, S. E., Speranza, M. C., Cho, C., & Chiocca, E. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 617

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update

Taplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J. R., Gleason, C. L., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K. V. I., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00374 · Cited by 606

MGMT testing—the challenges for biomarker-based glioma treatment

Wick, W., Weller, M., van den Bent, M. J., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M. E., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 599

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Butowski, N. A., Colman, H., de Groot, J., Omuro, A. M. P., Nayak, L., Wen, P. Y., Cloughesy, T. F., Marimuthu, A., Haidar, S., Perry, A., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov245 · Cited by 593

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Rodon, J. A., Soria, J., Berger, R., Miller, W. H., Rubin, E., Kugel, A., Tsimberidou, A. M., Saintigny, P., Ackerstein, A., Braña, I., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0424-4 · Cited by 590

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clément, P. M., Frénay, M., Campone, M., Baurain, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 587

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A. L., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 586

Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide

Grossman, S. A., Ye, X., Lesser, G. J., Sloan, A. E., Carraway, H. E., Desideri, S., & Piantadosi, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0774 · Cited by 580

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Herrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U. S., Sabel, M., Hau, P., Kortmann, R., Krex, D., Grauer, O. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31791-4 · Cited by 579

Longitudinal molecular trajectories of diffuse glioma in adults

Barthel, F. P., Johnson, K. C., Varn, F. S., Moskalik, A. D., Tanner, G., Kocakavuk, E., Anderson, K. J., Abiola, O., Aldape, K., Alfaro-Munoz, K. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1775-1 · Cited by 575

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

Law, I. G., Albert, N. L., Arbizu, J., Boellaard, R., Drzezga, A. E., Galldiks, N., la Fougère, C. J., Langen, K., Lopci, E., Lowe, V. J., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4207-9 · Cited by 560

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge

Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C., Heth, J., Salacz, M. E., Taylor, S. A., D’Andre, S. D., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1507-6 · Cited by 547

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

Szerlip, N. J., Pedraza, A. M., Chakravarty, D., Azim, M., McGuire, J., Fang, Y., Ozawa, T., Holland, E. C., Huse, J. T., Jhanwar, S. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114033109 · Cited by 546

Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance

Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.003 · Cited by 535

Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors

Capper, D., Weißert, S., Balß, J., Habel, A., Meyer, J., Jaeger, D., Ackermann, U., Tessmer, C., Korshunov, A., Zentgraf, H., et al. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00352.x · Cited by 534

Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma

Chaichana, K. L., Jusué-Torres, I., Navarro-Ramírez, R., Raza, S. M., Pascual-Gallego, M., Ibrahim, A., Hernandez-Hermann, M., Gomez, L., Ye, X., WEINGART, J. D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not137 · Cited by 531

TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL

Yan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H. S., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 531

Overcoming therapeutic resistance in glioblastoma: the way forward

Osuka, S., & Meir, E. G. V. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89587 · Cited by 526

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

Brat, D. J., Aldape, K., Colman, H., Figarella‐Branger, D., Fuller, G. N., Giannini, C., Holland, E. C., Jenkins, R. B., Kleinschmidt-DeMasters, B. K., Komori, T., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02127-9 · Cited by 523

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L., Mason, W. P., Weller, M., Hong, S., Musib, L. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 518

Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer

Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019) · Genes & Development · doi:10.1101/gad.324301.119 · Cited by 514

Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Law, M., Yang, S., Babb, J. S., Knopp, E. A., Golfinos, J. G., Zagzag, D., & Johnson, G. (2004) · PubMed Central · Cited by 508

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials

Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 489

Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study

Kickingereder, P., Isensee, F., Tursunova, I., Petersen, J., Neuberger, U., Bonekamp, D., Brugnara, G., Schell, M., Keßler, T., Foltyn‐Dumitru, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30098-1 · Cited by 485

Genomic correlates of response to immune checkpoint blockade

Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448

Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma

Grabowski, M. M., Recinos, P. F., Nowacki, A. S., Schroeder, J. L., Angelov, L., Barnett, G. H., & Vogelbaum, M. A. (2014) · Journal of neurosurgery · doi:10.3171/2014.7.jns132449 · Cited by 435

A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy

Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J. W., Greenman, C., Edkins, S., Bignell, G. R., Davies, H. R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0127 · Cited by 431

Response Assessment in Neuro-Oncology Clinical Trials

Wen, P. Y., Chang, S. M., van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 426

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

Lamborn, K. R., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Fink, K., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-062 · Cited by 417

Oncolytic Viruses and Their Application to Cancer Immunotherapy

Chiocca, E. A., & Rabkin, S. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0015 · Cited by 413

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution

Kim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. (2015) · Genome Research · doi:10.1101/gr.180612.114 · Cited by 411

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

Lombardi, G., Salvo, G. L. D., Brandes, A. A., Eoli, M., Rudà, R., Faedi, M., Lolli, I. R., Pace, A., Daniele, B., Pasqualetti, F., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30675-2 · Cited by 406

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

Reardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., Jones, K. L., Conway, A. S., Liao, X., Zhou, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0151 · Cited by 405

Cognitive Deficits before Treatment among Patients with Brain Tumors

Tucha, O. M., Smely, C., Preier, M., & Lange, K. W. (2000) · Neurosurgery · doi:10.1097/00006123-200008000-00011 · Cited by 399

Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy

Lan, X., Jörg, D. J., Cavalli, F. M. G., Richards, L. M., Nguyen, L. V., Vanner, R. J., Guilhamon, P., Lee, L., Kushida, M. M., Pellacani, D., et al. (2017) · Nature · doi:10.1038/nature23666 · Cited by 399

Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target

Wei, J., Marisetty, A., Schrand, B., Gabrusiewicz, K. R., Hashimoto, Y., Ott, M., Grami, Z. A., Kong, L., Ling, X., Caruso, H. G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121266 · Cited by 399

ESTRO-ACROP guideline “target delineation of glioblastomas”

Niyazi, M., Brada, M., Chalmers, A. J., Combs, S. E., Erridge, S., Fiorentino, A., Grosu, A., Lagerwaard, F. J., Minniti, G. C., Mirimanoff, R., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.12.003 · Cited by 389

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

Perry, J., Bélanger, K., Mason, W. P., Fulton, D. S., Kavan, P., Easaw, J. C., Shields, C., Kirby, S., Macdonald, D., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 379

Malignant Astrocytic Tumors: Clinical Importance of Apparent Diffusion Coefficient in Prediction of Grade and Prognosis

Higano, S., Yun, X., Kumabe, T., Watanabe, M., Mugikura, S., Umetsu, A., Sato, A., Yamada, T., & Takahashi, S. (2006) · Radiology · doi:10.1148/radiol.2413051276 · Cited by 374

Patterns of Care for Adults With Newly Diagnosed Malignant Glioma

Chang, S. M. (2005) · JAMA · doi:10.1001/jama.293.5.557 · Cited by 371

Corticosteroids compromise survival in glioblastoma

Pitter, K. L., Tamagno, I., Alikhanyan, K., Hosni-Ahmed, A., Pattwell, S. S., Donnola, S. B., Dai, C. S., Ozawa, T., Chang, M., Chan, T. A.-T., et al. (2016) · Brain · doi:10.1093/brain/aww046 · Cited by 368

Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma

Idbaïh, A., Canney, M. S., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier, N., Law-Ye, B., Leclercq, D., Bissery, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3643 · Cited by 367

Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets

Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 359

BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study

Kaley, T. J., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J. A., Lockhart, A. C., Keedy, V. L., Bielle, F., Hofheinz, R., Joly, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9990 · Cited by 357

Dose‐effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors

Vecht, C. J., Hovestadt, A., Verbiest, H. B. C., van der Vliet, H. J., & van Putten, W. L. J. (1994) · Neurology · doi:10.1212/wnl.44.4.675 · Cited by 352

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

Bady, P., Sciuscio, D., Diserens, A., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 351

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

Melin, B. S., Barnholtz‐Sloan, J. S., Wrensch, M., Johansen, C., Il’yasova, D., Kinnersley, B., Ostrom, Q. T., Labrèche, K., Chen, Y., Armstrong, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3823 · Cited by 351

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0284 · Cited by 350

Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function

Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T. J., Allison, J. P., Bigner, D. D., & Sampson, J. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2070 · Cited by 343

International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme

Roa, W., Kępka, L., Kumar, N., Sinaika, V., Matiello, J., Lomidze, D., Hentati, D., de Castro, D. G., Dyttus‐Cebulok, K., Drodge, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6606 · Cited by 340

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Weller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 339

An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers

Villa, G. R., Hulce, J. J., Zanca, C., Bi, J., Ikegami, S., Cahill, G. L., Gu, Y., Lum, K. M., Masui, K., Yang, H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.008 · Cited by 332

CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges

Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., & O’Rourke, D. M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy032 · Cited by 321

Risk factors for childhood and adult primary brain tumors

Ostrom, Q. T., Fahmideh, M. A., Cote, D. J., Muskens, I. S., Schraw, J. M., Scheurer, M. E., & Bondy, M. L. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz123 · Cited by 314

Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study

Stummer, W., Tonn, J., Mehdorn, H. M., Nestler, U., Franz, K., Goetz, C., Bink, A., & Pichlmeier, U. (2010) · Journal of neurosurgery · doi:10.3171/2010.3.jns097 · Cited by 313

Extent of Resection of Glioblastoma Revisited: Personalized Survival Modeling Facilitates More Accurate Survival Prediction and Supports a Maximum-Safe-Resection Approach to Surgery

Marko, N. F., Weil, R. J., Schroeder, J. L., Lang, F. F., Suki, D., & Sawaya, R. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.8886 · Cited by 311

Pseudoprogression of brain tumors

Thust, S. C., van den Bent, M. J., & Smits, M. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26171 · Cited by 308

European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma

Pace, A., Dirven, L., Koekkoek, J. A. F., Golla, H., Fleming, J., Rudà, R., Marosi, C., Rhun, É. L., Grant, R., Oliver, K. R., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30345-5 · Cited by 305

Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma

deCarvalho, A. C., Kim, H., Poisson, L., Winn, M. E., Mueller, C., Cherba, D., Koeman, J. M., Seth, S., Protopopov, A. I., Felicella, M. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0105-0 · Cited by 305

Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

Mathios, D., Kim, J. E., Mangraviti, A., Phallen, J. A., Park, C., Jackson, C. M., Garzón-Muvdi, T., Kim, E. S., Theodros, D., Polanczyk, M. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2942 · Cited by 304

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

Sandmann, T., Bourgon, R., Garcia, J., Li, C., Cloughesy, T. F., Chinot, O. L., Wick, W., Nishikawa, R., Mason, W. P., Henriksson, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5005 · Cited by 302

TRK inhibitors in TRK fusion-positive cancers

Drilon, A. E. D. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz282 · Cited by 300

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

Johanns, T. M., Miller, C. A., Dorward, I. G., Tsien, C. I., Chang, E. F., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R. E., Dahiya, S. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0575 · Cited by 297

Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity.

Hayashida, Y., Hirai, T., Morishita, S., Kitajima, M., Murakami, R., Korogi, Y., Makino, K., Nakamura, H., Ikushima, I., Yamura, M., et al. (2006) · PubMed Central · Cited by 296

NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma

Weiß, T., Weller, M., Gückenberger, M., Sentman, C. L., & Roth, P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1788 · Cited by 291

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

Wen, P. Y., Reardon, D. A., Armstrong, T. S., Phuphanich, S., Aiken, R. D., Landolfi, J. C., Curry, W. T., Zhu, J., Glantz, M., Peereboom, D. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0261 · Cited by 290

EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing

Francis, J. M., Zhang, C.-Z., Maire, C. L., Jung, J., Manzo, V. E., Adalsteinsson, V. A., Homer, H., Haidar, S., Blumenstiel, B., Pedamallu, C. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0879 · Cited by 287

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Brandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273

Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial

Rapp, S. R., Case, L. D., Peiffer, A. M., Naughton, M. M., Chan, M. D., Stieber, V. W., Moore, D. F., Falchuk, S. C., Piephoff, J. V., Edenfield, W. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.4508 · Cited by 270

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial

Suchorska, B., Weller, M., Tabatabai, G., Senft, C., Hau, P., Sabel, M., Herrlinger, U., Ketter, R., Schlegel, U. S., Marosi, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov326 · Cited by 268

Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection

Ringel, F. A., Pape, H., Sabel, M., Krex, D., Bock, H. C., Misch, M., Weyerbrock, A., Westermaier, T., Senft, C., Schucht, P., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov145 · Cited by 266

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial

Chiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D., Reardon, D. A., Wen, P. Y., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 264

Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis

Körber, V., Yang, J., Barah, P., Wu, Y., Stichel, D., Gu, Z., Fletcher, M. N. C., Jones, D., Hentschel, B., Lamszus, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.007 · Cited by 261

PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma

Perry, J., Julian, J. A., Laperrière, N., Geerts, W. H., Agnelli, G., Rogers, L., Malkin, M. G., Sawaya, R. A., Baker, R. I., Falanga, A., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03973.x · Cited by 249

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

Ellingson, B. M., Chung, C. D., Pope, W. B., Boxerman, J. L., & Kaufmann, T. J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2375-2 · Cited by 247

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

Belcaid, Z., Phallen, J. A., Zeng, J., See, A. P., Mathios, D., Gottschalk, C., Nicholas, S. E., Kellett, M. D., Ruzevick, J., Jackson, C. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101764 · Cited by 246

Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007

Leece, R., Xu, J. C., Ostrom, Q. T., Chen, Y., Kruchko, C. A., & Barnholtz‐Sloan, J. S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox091 · Cited by 235

Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas

Vogelbaum, M. A., Jost, S. C., Aghi, M. K., Heimberger, A. B., Sampson, J. H., Wen, P. Y., Macdonald, D., van den Bent, M. J., & Chang, S. M. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318223f5a7 · Cited by 231

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE

Alexander, B. M., Ba, S., Berger, M. S., Berry, D. A., Cavenee, W. K., Chang, S. M., Cloughesy, T. F., Jiang, T., Khasraw, M., Li, W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0764 · Cited by 229

Association Between Hyperglycemia and Survival in Patients With Newly Diagnosed Glioblastoma

Derr, R. L., Ye, X., Islas, M. U., Desideri, S., Saudek, C. D., & Grossman, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1098 · Cited by 228

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy

Kreth, F.-W., Thon, N., Simon, M., Westphal, M., Schackert, G., Nikkhah, G., Hentschel, B., Reifenberger, G., Pietsch, T., Weller, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt388 · Cited by 223

A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors

Glantz, M., Cole, B. F., Friedberg, M. H., Lathi, E. S., Choy, H., Furie, K. L., Akerley, W., Wahlberg, L. U., Lekos, A., & Louis, S. (1996) · Neurology · doi:10.1212/wnl.46.4.985 · Cited by 220

Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria

Tesileanu, C. M. S., Dirven, L., Wijnenga, M. M. J., Koekkoek, J. A. F., Vincent, A. J. P. E., Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., van Duinen, S. G., Smits, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz200 · Cited by 218

A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy

Butler, J. M., Case, L. D., Atkins, J., Frizzell, B., Sanders, G., Griffin, P., Lesser, G., McMullen, K., McQuellon, R., Naughton, M., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.076 · Cited by 214

Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients

Quillien, V., Lavenu, A., Karayan, L., Carpentier, C., Labussière, M., Lesimple, T., Chinot, O. L., Wager, M., Honnorat, J., Saïkali, S., et al. (2012) · Cancer · doi:10.1002/cncr.27392 · Cited by 213

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

Chi, A. S., Tarapore, R. S., Hall, M. D., Shonka, N., Gardner, S. L., Umemura, Y., Sumrall, A. L., Khatib, Z. A., Mueller, S., Kline, C., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03271-3 · Cited by 199

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

van den Bent, M. J., Eoli, M., Sepúlveda-Sánchez, J. M., Smits, M., Walenkamp, A., Frenel, J., Franceschi, E., Clement, P., Chinot, O. L., Vos, F. D., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz222 · Cited by 199

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

Cloughesy, T. F., Landolfi, J. C., Hogan, D. J., Bloomfield, S. M., Carter, B. S., Chen, C. C., Elder, J. B., Kalkanis, S. N., Kesari, S., Lai, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9784 · Cited by 195

Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors

Ellsworth, S. G. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.014 · Cited by 195

Phase I Study of GRN1005 in Recurrent Malignant Glioma

Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190

The Risk of Getting Worse: Surgically Acquired Deficits, Perioperative Complications, and Functional Outcomes After Primary Resection of Glioblastoma

Gulati, S., Jakola, A. S., Nerland, U. S., Weber, C., & Solheim, O. S. (2011) · World Neurosurgery · doi:10.1016/j.wneu.2011.06.014 · Cited by 189

A metabolic function of FGFR3-TACC3 gene fusions in cancer

Frattini, V., Pagnotta, S. M., Tala, Fan, J. J., Russo, M. V., Lee, S. B., Garofano, L., Zhang, J., Shi, P., Lewis, G., et al. (2018) · Nature · doi:10.1038/nature25171 · Cited by 189

Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells

Carruthers, R., Ahmed, S. U., Ramachandran, S., Strathdee, K. E., Kurian, K. M., Hedley, A., Gomez-Roman, N., Kalna, G., Neilson, M., Gilmour, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0569 · Cited by 189

Addressing Diffuse Glioma as a Systemic Brain Disease With Single-Cell Analysis

Capper, D. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.2910 · Cited by 187

Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement

Chang, K., Beers, A. L., Bai, H. X., Brown, J. M., Ly, I., Li, X., Senders, J. T., Kavouridis, V. K., Boaro, A., Su, C., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz106 · Cited by 182

Prophylactic Anticonvulsants in Patients with Brain Tumour

Forsyth, P. A., Weaver, S., Fulton, D. S., Brasher, P. M. A., Sutherland, G. R., Stewart, D., Hagen, N. A., Barnes, P. J., Cairncross, J. G., & DeAngelis, L. M. (2003) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100053361 · Cited by 180

The DNA Damaging Revolution: PARP Inhibitors and Beyond

Yap, T. A., Plummer, R., Azad, N. S., & Helleday, T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238473 · Cited by 178

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma

Wheeler, L. A., Manzanera, A. G., Bell, S. D., Cavaliere, R., McGregor, J. M., Grecula, J. C., Newton, H. B., Lo, S. S.-M., Badie, B., Portnow, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now002 · Cited by 176

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

Wen, P. Y., Chang, S., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not247 · Cited by 174

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048

Glioblastoma and Other Primary Brain Malignancies in Adults

Schaff, L. R., & Mellinghoff, I. K. (2023) · JAMA · doi:10.1001/jama.2023.0023 · Cited by 1,411

Network pharmacology: curing causal mechanisms instead of treating symptoms

Nogales, C., Mamdouh, Z. M., List, M., Kiel, C., Casas, A. I., & Schmidt, H. H. H. W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.004 · Cited by 1,251

Glioma

Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M. K., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 693

Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma

Hara, T., Chanoch-Myers, R., Mathewson, N. D., Myskiw, C., Atta, L., Bussema, L., Eichhorn, S. W., Greenwald, A., Kinker, G. S., Rodman, C., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.002 · Cited by 613

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

Miller, J. J., Castro, L. N. G., McBrayer, S. K., Weller, M., Cloughesy, T. F., Portnow, J., Andronesi, O. C., Barnholtz‐Sloan, J. S., Baumert, B. G., Berger, M. S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac207 · Cited by 265

Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma

Galanis, E., Wen, P. Y., de Groot, J., & Weller, M. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.08.007 · Cited by 3

Current Pharmacotherapeutic Strategies in Diffuse Gliomas: Focus on Glioblastoma, IDH-Wildtype, and Emerging Targeted Therapies for IDH-Mutant Tumors

Dynarowicz, K., Smolak, B., Bartusik‐Aebisher, D., Guz, W., Henrykowska, G. A., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19010148 · Cited by 4

Update on glioblastoma: Biology, clinical management and emerging therapeutic strategies (Review)

Ahmed, S., & Abdalla, B. A. (2026) · World Academy of Sciences Journal · doi:10.3892/wasj.2026.439

Glioblastoma

Wirsching, H. G., Galanis, E., & Weller, M. (2016) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-124236